Video Experimental Relacionado
Updated: Aug 2, 2026
09:54
Identification and Characterization of Protein Glycosylation using Specific Endo- and Exoglycosidases
Published on: December 26, 2011
Glycoinsulinas: insulinas con exhibición de sialiloligosacáridos dendríticos que muestran una prolongada actividad
Masaaki Sato1, Tetsuya Furuike, Reiko Sadamoto
1Division of Biological Sciences, Graduate School of Science, Frontier Research Center for Post-Genomic Science and Technology, Hokkaido University, Kita 21 Nishi 11, Sapporo 001-0021, Japan.
Journal of the American Chemical Society
|October 28, 2004
Resumen
Modificación de la insulina con ácido siálico utilizando alfa2,6-sialiltransferasa (alfa2,6-SiaT) y transglutaminasa (TGase) con efectos prolongados de reducción de la glucosa en ratones hiperglucémicos. La glicinoinsulina trisializada demostró un retraso significativo en la recuperación del nivel de glucosa.
Área de la Ciencia:
- La bioquímica es la bioquímica.
- Glucobiología Glucobiología.
- Farmacología Farmacología.
Sus antecedentes:
- La terapia con insulina es crucial para el manejo de la diabetes.
- Mejorar el perfil farmacocinético de la insulina puede mejorar el control glucémico.
- Se sabe que los residuos de ácido siálico influyen en la vida media de las proteínas y en la actividad biológica.
Objetivo del estudio:
- Para modificar enzimáticamente las insulinas mutantes con oligosacáridos sializados.
- Investigar el impacto de la sialización en la eficacia y duración de la insulina para reducir la glucosa.
- Evaluar el potencial de la glicinoinsulina como agente terapéutico de acción prolongada.
Principales métodos:
- La insulina mutante fue modificada utilizando transglutaminasa (TGase) para unir un residuo de glutamina accesible.
- La alfa2,6-sialiltransferasa (alfa2,6-SiaT) se empleó para sializar las cadenas de azúcar en la insulina modificada.
- Las variantes de insulina sializadas, Sia2,6-di-LacNAc-Ins (((B-F1Q) y Sia2,6-tri-LacNAc-Ins (((B-F1Q), fueron administradas a ratones con hiperglucemia.
Principales resultados:
- Tanto las glicosilinas di- como las trisializadas demostraron efectos prolongados de reducción de la glucosa en comparación con las insulinas nativas o modificadas por lactosa.
- La presencia de ácido siálico se identificó como un factor clave para lograr una duración terapéutica prolongada.
- Sia2,6-tri-LacNAc-Ins ((B-F1Q) retrasó significativamente la normalización de los niveles de glucosa en ratones con hiperglucemia.
Conclusiones:
- La sianilación enzimática de la insulina puede crear variantes de glucoinsulina de acción prolongada.
- Los residuos de ácido siálico juegan un papel crítico en la extensión de las propiedades farmacocinéticas y farmacodinámicas de la insulina.
- Estos hallazgos sugieren una estrategia prometedora para desarrollar formulaciones mejoradas de insulina para el tratamiento de la diabetes.
Más Videos Relacionados
Videos de Conceptos Relacionados
01:17Oral Hypoglycemic Agents: Sulfonylureas
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...